Advertisement
U.S. markets open in 3 hours 39 minutes
Advertisement

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
24.39+3.61 (+17.37%)
At close: 04:00PM EST
24.60 +0.21 (+0.86%)
Pre-Market: 05:39AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
Previous Close20.78
Open21.00
Bid24.39 x 900
Ask25.00 x 1000
Day's Range20.92 - 24.84
52 Week Range12.32 - 45.43
Volume2,313,855
Avg. Volume1,243,460
Market Cap1.029B
Beta (5Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-2.29
Earnings DateFeb 26, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target Est99.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SAVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cassava Sciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/25/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Motley Fool

    Why Cassava Sciences Stock Soared Today

    Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.

  • GlobeNewswire

    Cassava Sciences Appoints Three New Members to its Board of Directors

    Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i

  • InvestorPlace

    7 High-Risk, High-Reward Stocks for the Extreme Contrarian

    Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. Basically, while the rewards for when the stars align can be enormously high, they rarely align. In the long run, it’s better to stick with established investing protocols. At the same time, high-risk, high-reward stocks offer tremendous leverage, usually within a near-term framework. Also, it’s rare that people t